Status epilepticus admissions during the COVID-19 pandemic in Salzburg-A population-based study
- PMID: 33140437
- PMCID: PMC7756208
- DOI: 10.1111/epi.16737
Status epilepticus admissions during the COVID-19 pandemic in Salzburg-A population-based study
Abstract
Several emergencies were admitted less frequently to the hospital during the coronavirus disease 2019 (COVID-19) pandemic. To investigate whether this also occurred with status epilepticus (SE) we compared admissions due to first SE from March to April 2020 ("Time of COVID," TOC) with January to February 2020 ("pre-COVID," preCOV). We also compared admission numbers in TOC and preCOV with the respective 2-month periods in 2018 and 2019 in a retrospective cohort analysis. Two investigators independently searched the hospital patient database for various forms of SE. There was no significant change in the 2-month incidences of first SE in the city of Salzburg from preCOV of 6.1 (95% confidence interval [CI] 2.9-12.3) to TOC of 6.9/100 000 adults (95% CI 3.4-13.3). Admission numbers did not differ significantly from previous years. Estimated adjusted incidence was in line with a recent 5-year epidemiological study in Salzburg. However, a trend toward less-frequent nonconvulsive SE (NCSE) and loss of female predominance were indirect hints of underdiagnosing SE. In contrast to other medical conditions, SE most often presents clinically with impaired consciousness, which may promote admission to emergency departments even in times of lock-down. Further research of medical support of women and patients with NCSE during pandemic-related restrictions is warranted.
Keywords: epidemiology; incidence; protection; risk; wristband.
© 2020 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Conflict of interest statement
Markus Leitinger reports travel grants from UCB Pharma and speaker`s honoraria from Eisai, unrelated to the present work. Alexandra Rohracher received travel support and speaker`s honoraria from Eisai, unrelated to the present work. Gudrun Kalss received travel support and speaker`s honoraria from Eisai and UCB, unrelated to the present work. Eugen Trinka reports paid consultancy for UCB, Eisai, Bial, Medtronic, EVER Pharma, Biogen, Takeda, LivaNova, NewBridge, Sunovion, GW Pharmaceuticals, Marinus, and Arvelle; research funding (directly, or to his institution) from GSK, Biogen, Eisai, Novartis, Red Bull, Bayer, and UCB; speaker's honoraria from Bial, Böhringer Ingelheim, Eisai, EVER Pharma, GSK, LivaNova, NewBridge, Novartis, Sanofi, Sandoz, and UCB. ET is the CEO of Neuroconsult Ges.m.b.H. ET receives grants from the Austrian Science Fund (FWF), Österreichische Nationalbank, and the European Union, unrelated to the present work. Kai‐Nicolas Poppert, Matthias Mauritz, Fabio Rossini, Georg Zimmermann, Giorgi Kuchukhidze, Julia Höfler, Pilar Bosque‐Varela, Rudolf Kreidenhuber, Kamila Volna, Caroline Neuray, Teia Kobulashvili, Claudia A. Granbichler, and Uwe Siebert report no conflicts of interests.
Figures

References
-
- Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung SH, et al. The Covid‐19 pandemic and the incidence of acute myocardial infarction. N Engl J Med. 2020;383(7):691–3. - PubMed
-
- Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus–Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56:1515–23. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous